Limoli Paolo Giuseppe, Vingolo Enzo Maria, Limoli Celeste, Nebbioso Marcella
Low Vision Research Centre of Milan, p. Sempione 3, 20145 Milan, Italy.
Department of Ophthalmology, A. Fiorini Hospital, Terracina, Polo Pontino, Sapienza University of Rome, p. le A. Moro 5, 00185 Rome, Italy.
Antioxidants (Basel). 2020 Oct 13;9(10):983. doi: 10.3390/antiox9100983.
Both tissue repair and regeneration are a priority in regenerative medicine. Retinitis pigmentosa (RP), a complex retinal disease characterized by the progressive loss of impaired photoreceptors, is currently lacking effective therapies: this represents one of the greatest challenges in the field of ophthalmological research. Although this inherited retinal dystrophy is still an incurable genetic disease, the oxidative damage is an important pathogenetic element that may represent a viable target of therapy. In this review, we summarize the current neuroscientific evidence regarding the effectiveness of cell therapies in RP, especially those based on mesenchymal cells, and we focus on their therapeutic action: limitation of both oxidative stress and apoptotic processes triggered by the disease and promotion of cell survival. Cell therapy could therefore represent a feasible therapeutic option in RP.
组织修复和再生都是再生医学的重点。视网膜色素变性（RP）是一种复杂的视网膜疾病，其特征是受损的光感受器逐渐丧失，目前缺乏有效的治疗方法：这是眼科研究领域最大的挑战之一。尽管这种遗传性视网膜营养不良仍然是一种无法治愈的遗传疾病，但氧化损伤是一个重要的致病因素，可能是一个可行的治疗靶点。在这篇综述中，我们总结了目前关于细胞疗法治疗RP有效性的神经科学证据，特别是基于间充质细胞的疗法，并重点关注其治疗作用：限制疾病引发的氧化应激和凋亡过程，促进细胞存活。因此，细胞疗法可能是RP一种可行的治疗选择。
